The tumor mapping will let them link specific cell signaling activity to pathways activated by the treatment - then they can get more biomarker info and define what specific cell signalling activity is linked to what outcome/prognosis. So you're right - once again it's about targeted therapy. This type of signaling info isn't useful to many agents but the new targeted molecular therapies gain much from it. If ctix makes it thru phII - I think their phIII will be amazing - they will know so much going in. Their goals will be near-perfectly constructed with the mapping and biomarker and scan info etc... and their population will be a near-perfect fit for their drug. The trial will be economical, streamlined, not a wasted penny.